Thyroid Eye Disease clinical trials at UCSF
2 research studies open to eligible people
VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)
open to eligible people ages 18 years and up
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). This clinical trial will evaluate the safety, tolerability and pharmacokinetics (the concentration of drug in the blood over time) of VRDN-001 in healthy volunteers and in patients with TED. Study participants with TED will also be evaluated over time for changes in their signs and symptoms of TED compared to their baseline measurements.
San Francisco, California and other locations
Batoclimab in Participants With Active Thyroid Eye Disease
open to eligible people ages 18 years and up
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
San Francisco, California and other locations
Last updated: